Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Dexcom

Explore full profile

Continuous Glucose Monitoring

San Diego, United StatesFounded 1999Health Tech & Medtech
Valuation $31B Market cap · Aug/2026
Revenue $5.23B Latest reported FY
EBITDA $1.66B Latest reported FY

At a glance

Founded
1999
Headquarters
San Diego, United States
Listing
IPO 2005
Sector
Health Tech & Medtech
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning Dexcom.

See all news

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later7 investors entered at this stage

  • St. Paul Venture Capital
  • Canaan
  • Warburg Pincus
  • Windamere Venture Partners
  • Federated Hermes
  • Fog City Capital
  • RWI Group
Employees mapped 8,882 incl. 69 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 16 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 6 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
38 countries with
team presence
🇺🇸 United States60.7%
🇵🇭 Philippines9.7%
🇲🇾 Malaysia8.7%
🇱🇹 Lithuania5.1%
🇬🇧 United Kingdom3.7%
Top 5 of 38 shown
Web traffic by country
2.5M monthly visits
across markets
🇺🇸 United States77%
🇩🇪 Germany3.5%
🇬🇧 United Kingdom2.3%
🇨🇦 Canada2.3%
🇦🇺 Australia2.1%
Top 5 markets shown

Patents

Estimated portfolio value
$842M

499 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Dexcom was the backer or acquirer, 2012–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

9 deals across Dexcom's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where Dexcom deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        Dexcom's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        9 of 9 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Dexcom on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Dexcom on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.